ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2556

Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN

Ana Malvar1, Valeria Alberton 2, Cecilia Recalde 2, Sheng Gao 3 and Michael Maldonado 3, 1Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina, 2Hospital Fernandez, Buenos Aires, Argentina, 3Bristol-Myers Squibb, Princeton, NJ

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: biopsies, drug therapy and proteinuria, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for determining the length of maintenance therapy remains a challenge. Most clinicians use a combination of clinical parameters and length of treatment. Unfortunately, there can be a disassociation between clinical parameters and renal biopsies, the gold standard for assessing disease activity.1 Here we present the findings of repeat renal biopsies and a post hoc analysis of their correlation with clinical outcomes from a single site in ALLURE (NCT01714817), a randomized, double-blind Phase III study comparing abatacept (ABA) with placebo (PBO) on background MMF and CS in patients with active Class III or IV LN.

Methods: We evaluated 20 patients from a single site who underwent repeat kidney biopsy (Bx) as part of standard practice. The first Bx was for diagnostic purpose and the second Bx was performed after study discontinuation for clinical decision making. Bx were processed using standard techniques and read, classified using International Society of Nephrology/Renal Pathology Society 2003 Classification and scored using the National Institute of Health activity and chronicity indices (AI/CI) by a single pathologist, blinded to clinical data.2 Renal pathology findings were correlated with clinical outcomes collected during study participation.

Results: 20/25 patients randomized at the site had paired pre- and post-treatment Bx to be analyzed (ABA n=8; PBO n=12). Demographics and disease characteristics at baseline, duration of therapy and mean time between Bx were comparable (Table 1). 4 patients discontinued treatment, all due to lack of efficacy (ABA n=1; PBO n=3). Most patients achieved a urine protein to creatinine ratio (UPCR) ≤0.5 at least once during therapy (ABA 6/8; PBO 8/12) but mean UPCR at Year 1 was lower in the ABA arm (ABA 0.56; PBO 1.53). While the groups had comparable AI and CI scores at baseline, the ABA group had a lower mean score at the 2nd Bx (0.8 vs PBO 2.9; Table 1). 6/8 of the ABA group had an AI of 0 on repeat Bx vs 5/12 in PBO group (Fig. 1). 2 PBO patients had UPCR ≤0.5 but had some activity on 2nd Bx; 2 ABA patients without activity on 2nd Bx had UPCR >0.5 (0.6 and 0.8). After an average of >2 years of treatment, most responders were classified as III (C) on a repeat Bx (Table 2). Overall safety was comparable in both groups; 2 ABA patients had serious infections (pneumonia and gastroenteritis) that did not lead to discontinuation.

Conclusion: Repeat kidney Bx in patients with active LN after prolonged therapy can reveal discrepancies between clinical and histological responses. Most patients treated with abatacept showed lack of activity even with mild, residual proteinuria. Better methodologies are needed to detect renal activity and improve clinical decision making in patients with LN.

References

  1. Roseman DA, et al. Nephrol Dial Transplant 2017;32:1344–50.
  2. Austin HA 3rd, et al. Am J Med 1983;75:382–91.

Writing support: Carol Keys, Caudex; funding: Bristol-Myers Squibb


Disclosure: A. Malvar, None; V. Alberton, None; C. Recalde, None; S. Gao, Bristol-Myers Squibb, 1, 3, 4; M. Maldonado, Bristol-Myers Squibb, 1, 3.

To cite this abstract in AMA style:

Malvar A, Alberton V, Recalde C, Gao S, Maldonado M. Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/histologic-findings-from-paired-renal-biopsies-and-clinical-outcomes-results-from-a-single-site-in-the-phase-iii-study-of-abatacept-in-patients-with-proliferative-ln/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histologic-findings-from-paired-renal-biopsies-and-clinical-outcomes-results-from-a-single-site-in-the-phase-iii-study-of-abatacept-in-patients-with-proliferative-ln/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology